Pooled analysis of five-year data from two phase 3 studies supports overall survival
Incyte announced pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall survival findings and suggests earlier treatment with Jakafi® (ruxolitinib) may result in an improved survival advantage. December 04, 2016